A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Margaret Hux; Denise Zou; Esprit Ma; Peter Sajosi; Andreas Engstrom; Ross Selby; Eugene Benson; Andrew Briggs; Vijayveer Bonthapally

doi:10.36469/9820

JHEOR

Articles
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:24995/feed

Oncology

Vol. 4, Issue 2, 2017

October 26, 2016 EDT

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Margaret Hux, Denise Zou, Esprit Ma, Peter Sajosi, Andreas Engstrom, Ross Selby, Eugene Benson, Andrew Briggs, Vijayveer Bonthapally,

incremental cost-effectiveness ratioquality-adjusted life yearchemotherapysystemic anaplastic large cell lymphomabrentuximab vedotincost-effectiveness

ccby-4.0

• https://doi.org/10.36469/9820

JHEOR

Hux M, Zou D, Ma E, et al. A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. JHEOR. 2016;4(2):188-203. doi:10.36469/9820

Save article as...▾

View more stats

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.